Ifp Advisors, Inc Biogen Inc. Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Biogen Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 737 shares of BIIB stock, worth $107,948. This represents 0.01% of its overall portfolio holdings.

Number of Shares

737

Previous 817 9.79%

Holding current value

$107,948

Previous $176,000 3.41%

% of portfolio

0.01%

Previous 0.01%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$190.52 - $236.72 $15,241 - $18,937	-80 Reduced 9.79%	737 $170,000
Q1 2024 Jul 30, 2024	SELL	$212.02 - $267.71 $212 - $267	-1 Reduced 0.12%	817 $176,000
Q4 2023 Jan 09, 2024	BUY	$222.59 - $267.94 $2,893 - $3,483	13 Added 1.61%	818 $211,000
Q3 2023 Oct 12, 2023	SELL	$253.3 - $285.89 $7,092 - $8,004	-28 Reduced 3.36%	805 $206,000
Q2 2023 Aug 04, 2023	BUY	$275.25 - $318.06 $68,262 - $78,878	248 Added 42.39%	833 $237,000
Q1 2023 Apr 18, 2023	SELL	$256.56 - $292.34 $136,489 - $155,524	-532 Reduced 47.63%	585 $162,000
Q4 2022 Feb 07, 2023	SELL	$252.44 - $306.72 $277,179 - $336,778	-1,098 Reduced 49.57%	1,117 $333,000
Q3 2022 Nov 08, 2022	BUY	$194.69 - $268.46 $29,592 - $40,805	152 Added 7.37%	2,215 $667,000
Q2 2022 Sep 06, 2022	BUY	$187.54 - $223.02 $385,582 - $458,529	2,056 Added 29371.43%	2,063 $616,000
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $385,582 - $458,529	-2,056 Reduced 99.66%	7 $2,000
Q1 2022 Sep 06, 2022	BUY	$193.77 - $244.14 $229,617 - $289,305	1,185 Added 134.97%	2,063 $434,000
Q1 2022 Aug 08, 2022	BUY	$193.77 - $244.14 $49,992 - $62,988	258 Added 41.61%	878 $184,000
Q4 2021 Jan 12, 2022	SELL	$223.92 - $287.77 $2.29 Million - $2.94 Million	-10,232 Reduced 94.29%	620 $151,000
Q3 2021 Oct 06, 2021	BUY	$282.99 - $369.05 $89,990 - $117,357	318 Added 3.02%	10,852 $3.08 Million
Q2 2021 Jul 13, 2021	BUY	$259.0 - $414.71 $141,932 - $227,261	548 Added 5.49%	10,534 $3.65 Million
Q1 2021 Apr 30, 2021	BUY	$242.95 - $284.63 $523,314 - $613,093	2,154 Added 27.5%	9,986 $2.79 Million
Q4 2020 Jan 25, 2021	BUY	$236.26 - $355.63 $256,342 - $385,858	1,085 Added 16.08%	7,832 $1.9 Million
Q3 2020 Oct 29, 2020	BUY	$264.77 - $305.71 $141,387 - $163,249	534 Added 8.59%	6,747 $1.91 Million
Q2 2020 Aug 05, 2020	BUY	$258.66 - $342.55 $1.37 Million - $1.82 Million	5,313 Added 590.33%	6,213 $1.63 Million
Q1 2020 May 12, 2020	SELL	$268.85 - $341.04 $223,952 - $284,086	-833 Reduced 48.07%	900 $276,000
Q4 2019 Jan 17, 2020	BUY	$220.06 - $304.07 $40,270 - $55,644	183 Added 11.81%	1,733 $525,000
Q3 2019 Nov 07, 2019	BUY	$217.44 - $243.88 $231,138 - $259,244	1,063 Added 218.28%	1,550 $356,000
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $139,561 - $218,290	-644 Reduced 56.94%	487 $112,000
Q4 2018 Jan 23, 2019	SELL	$278.5 - $352.75 $71,296 - $90,304	-256 Reduced 18.46%	1,131 $340,000
Q3 2018 Oct 25, 2018	SELL	$293.51 - $383.83 $27,589 - $36,080	-94 Reduced 6.35%	1,387 $0
Q2 2018 Aug 07, 2018	SELL	$257.52 - $306.91 $460,188 - $548,448	-1,787 Reduced 54.68%	1,481 $0
Q1 2018 Jun 03, 2019	BUY	$260.13 - $367.91 $384,472 - $543,770	1,478 Added 82.57%	3,268 $1.04 Million
Q1 2018 May 09, 2018	SELL	$260.13 - $367.91 $384,472 - $543,770	-1,478 Reduced 45.23%	1,790 $0
Q4 2017 Jan 24, 2018	SELL	$307.64 - $344.58 $19,073 - $21,363	-62 Reduced 1.86%	3,268 $0
Q3 2017 Oct 30, 2017	BUY	$281.15 - $329.69 $299,705 - $351,449	1,066 Added 47.08%	3,330 $1.04 Million
Q2 2017 Jun 03, 2019	BUY	N/A	146 Added 6.89%	2,264 $614,000
Q1 2017 Jun 03, 2019	BUY	N/A	174 Added 8.95%	2,118 $579,000
Q4 2016 Jun 03, 2019	BUY	N/A	576 Added 42.11%	1,944 $551,000
Q2 2016 Jun 03, 2019	BUY	N/A	881 Added 180.9%	1,368 $331,000
Q1 2016 Jun 03, 2019	BUY	N/A	487	487 $112,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account